Business Context and Reporting Period
This Form 8-K filing by Cortexyme, Inc. (not Quince Therapeutics, Inc.) covers the period ending May 13, 2019. The report details the closing of the Company's initial public offering (IPO) and the concurrent amendment of its corporate governance documents.
Key Financial Metrics
- Capital Raised: The Company raised approximately $78.1 million in net proceeds from the IPO.
- Offering Structure: The offering consisted of 4,412,000 shares priced at $17.00 per share, plus a full exercise of the underwriters' option to purchase an additional 661,800 shares.
- Revenue and Profit: The filing text does not provide revenue, profit, or cash flow figures for the reporting period.
- Debt and Liquidity: Specific debt levels or liquidity ratios are not disclosed in this document; however, the net proceeds significantly increased cash liquidity.
Material Changes
The primary material change is the transition from a private to a public company. Key changes include:
- Capital Structure: Issuance of new common stock registered on the Nasdaq Stock Market under the symbol CRTX.
- Corporate Governance: Filing of an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws effective as of the IPO closing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosures referenced in the final prospectus. The document focuses strictly on the mechanics of the IPO closing and corporate amendments.
Investor Verification Checklist
- Verify the final prospectus (File No. 333-230853) for detailed use of proceeds and risk factors.
- Confirm the trading status of shares under the symbol CRTX on the Nasdaq Stock Market.
- Review the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific shareholder rights and capital stock details.
- Note that the registrant name in the filing is Cortexyme, Inc., not Quince Therapeutics, Inc.